

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for June 19, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

NNDSS Modernization Initiative Technical Assistance Coordination Team Update

June 19, 2015

NMI Overall Updates

- The NMI team held a kickoff meeting on 6/5/15 with the CDC Division of Vector-Borne Disease to initiate work on the Arboviral Disease Message Mapping Guide (MMG) for HL7 case notifications and on 6/9/15 with the CDC National Center for Immunization and Respiratory Diseases to initiate work on the Varicella MMG.
- Staff members from all three NMI partners—CDC, CSTE, and APHL—shared NMI accomplishments and plans during several NMI-related sessions at the CSTE Annual Conference, held in Boston, Massachusetts, this week from 6/14/15 to 6/18/15.

Message Mapping Guide Development Updates

- The MMG Development Team posted the list of conditions to use with the Generic v2 MMG only to the Draft MMG Web site at <http://www.cdc.gov/nndss/message-mapping-guides.html> in the Stage II, Pilot Test-ready section adjacent to the Generic v2 MMG.
- **Message Mapping Guide (MMG) Status Updates:**
 - **Mumps and Pertussis MMGs ([Stage 1—Draft Phase](#)):**
 - The second external review period for the restructured Mumps and Pertussis MMGs closed on 5/22/15.
 - The 50 comments received from four states (Washington, California, Virginia, and Minnesota) have been addressed, and the MMG Development Team expects to share test-ready versions of the MMGs with the CDC programs this week.
 - **Congenital Syphilis and STD MMGs ([Stage II—Pilot Test-ready Draft Phase](#))**
 - The MMG Development Team posted pilot test-ready versions of the STD and Congenital Syphilis MMGs and their artifacts to the Draft MMG Web Site.
 - **Generic v2 and Hepatitis MMGs ([Stage II—Pilot Test-ready Draft Phase](#))**
 - The MMG Development Team posted pilot test-ready versions of the Generic v2 and Hepatitis MMGs and their artifacts to the Draft MMG Web Site.
 - No guides are in [Stage III—Final MMG Phase](#) at this time.

Message Validation, Processing, and Provisioning System Updates

- The Message Validation, Processing, and Provisioning System (MVPS) developer delivered the message processing functions code for Generic v2, STD, and Hepatitis to CDC on 6/5/15.
 - The MVPS Team is now installing this code and, once completed, will begin technical acceptance testing.
- The MVPS Team continues to work on finalizing the data provisioning requirements and data dictionary mapping for Generic v2, Hepatitis, and STD in conjunction with the CDC Surveillance Operations Team and Message and Vocabulary Team.
 - The MVPS Team delivered the Generic v2 requirements to the MVPS developer on 6/4/15. The MVPS team will schedule time with the CDC programs to discuss the Generic v2 data provisioning design and approach.
 - The team is now focused on completing the Hepatitis and STD data provisioning requirements in that order.
 - The team's goal is to submit requirements before the end of July 2015, with a target of submitting Hepatitis requirements by the end of June 2015 so that the MVPS developer can provide feedback.
- The MVPS Team received the authority to operate (ATO) from the CDC Office of the Chief Information Security Officer (OCISO) for the multi-server environment on 6/6/15.
 - The MVPS Team is now preparing to transition production to the multi-server environment.
 - The MVPS Team will then submit a change request (CR) to OCISO to incorporate an ATO for the security code in the multi-server environment.
- The MVPS Dashboard and message processing code is being installed in the test environment. Once the code is installed, technical acceptance testing of it will start.
- The updated code for the Message Evaluation and Testing Service (METS) tool is expected to be installed and tested in the development environment earlier than the MVPS Dashboard. The MVPS Team plans to make the METS code available to jurisdictions as soon as possible, with a target date of mid-June, to support jurisdictions in their independent validation testing of Hepatitis, STD, and Generic v2 messages.
- The MVPS Team is finalizing Secure Access Management Services (SAMS) training documentation in preparation to train pilot jurisdictions on SAMS, expected to occur on 6/24/15.

Technical Assistance Updates

- To assist jurisdictions using MAVEN surveillance systems, Lesliann Helmus, Michele Hoover, and Jason Hall will participate in the MAVEN User Group Meeting to be held after this week's CSTE Annual Conference in Boston.
- **Update on Jurisdiction Implementation:** Note that all pilot jurisdictions are working on both Hepatitis and STD at the same time and are using the test messages and scenarios developed by CDC. Additional test messages may be developed by the jurisdictions.
 - **California:**
 - The APHL Technical Assistance Team and the technical team from California identified an approach for implementing case notification HL7 messaging, set up and tested the PHIN Messaging System (PHIN MS) transport, installed the Rhapsody validator, and completed the initial gap analysis for STD and Hepatitis.

- The teams continue to work on implementing the messaging plan, mapping to the data extract, and customizing the Rhapsody route for California.
 - **Minnesota:**
 - The APHL Technical Assistance Team and the technical team from Minnesota established an architectural solution for case notification messaging and installed the Rhapsody validator.
 - Minnesota has completed the gap analysis for Hepatitis and is in progress for STD.
 - The state is currently preparing to implement the designed technical solution.
 - The PHIN MS transport has been tested, and a permanent route will be installed when the customized Rhapsody route is implemented.
 - **Oregon**
 - The APHL Technical Assistance team was onsite at Oregon last week (6/9/15 to 6/11/15).
 - Oregon has completed the gap analysis for Hepatitis and STD and installed the Rhapsody route and validator. The full suite of HL7 test messages for Hepatitis is nearly complete, and the STD test message suite is in progress. The APHL Technical Assistance Team is reviewing and providing feedback on test messages as they are created.
 - **Michigan:**
 - Michigan is building the full suite of test messages for Hepatitis and STD in preparation for internal validation. The APHL Technical Assistance Team is reviewing and providing feedback on test messages as they are created.
 - **Florida:**
 - Florida is working on the gap analysis for Hepatitis and STD.
 - Florida will pilot the Mirth Channel created by the NMI Technical Assistance Team. The Mirth validator has been installed and tested in the Florida system.
 - The PHIN MS transport has been set up and tested.
- CSTE will work with all of the pilot jurisdictions to evaluate the NMI TA efforts.
- Reminder about MMG status:
 - MMGs in Stages I and II are considered draft and may be revised until the time they are finalized.
 - Those jurisdictions selected for pilot testing of the test-ready versions (Stage II) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
 - All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage III) have been posted.
- For more information about technical assistance:
 - Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
 - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at laura.carlton@aphl.org.

- For non-pilot jurisdictions: If you have questions or would like to request TA through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.